RECEPTOR.AI

Name: RECEPTOR.AI
Brand: RECEPTOR.AI

AI Native

RECEPTOR.AI is a TechBio drug-discovery platform that combines machine learning, agent-based AI orchestration, and physics-based modeling to support virtual screening, SAR-driven lead optimization, and design workflows across small molecules, peptides, and induced-proximity biologic modalities.

Est 2021

LinkedIn 10K|Web traffic 1K|FTEs 42

Published Jun 25, 2026

01Common complaints

1. Formal security certification requirement - If procurement requires publicly documented SOC 2 Type II or ISO 27001 certification prior to vendor consideration, RECEPTOR.AI’s public materials do not show these certifications and the vendor may not pass initial screening based solely on public information. 2. Need for an off-the-shelf, self-serve computational chemistry tool with a large public user community - Organizations seeking a widely adopted, self-serve solution with extensive public training resources may prefer established toolkits or vendors with larger public communities. 3. Lack of experimental feedback capability - Programs without assay throughput or synthesis capacity to support iterative design-test cycles may see limited ROI from any AI discovery platform. 4. Requirement for extensive public reviews - If vendor selection heavily depends on Gartner/G2/TrustRadius-style public reviews, RECEPTOR.AI’s public presence appears limited and will require reference checks under NDA and pilots. 5. Expectation of guaranteed clinical translation outcomes - RECEPTOR.AI focuses on preclinical discovery work; improvements in computational metrics do not guarantee clinical success.

Deal disqualifiers

Formal requirement for publicly documented SOC2/ISO27001 evidence prior to vendor consideration
Need for an off-the-shelf, self-serve SaaS trial with public pricing
Requirement for numerous public customer reviews or references without NDAs

Limitations acknowledged by vendor or present in peer-reviewed artifacts

Vendor materials generally emphasize ongoing improvement but do not list extensive limitations publicly. The ArtiDock paper notes broader issues in ML docking, such as chemical validity of predicted poses, and identifies future work areas (improving geometrical/chemical validity and native scoring).

Roadmap and continuity

Some vendor posts indicate future integrations (e.g., with third-party cloud APIs) and continued model updates; timelines are not always definitive.

Scale considerations

No explicit scale-breaking points are disclosed. Third-party technical content suggests large-scale screening is feasible with sufficient GPU resources, but buyers should clarify cost and throughput assumptions.

Security and compliance gaps

No publicly documented SOC2/ISO certifications were located.
Limited public enterprise feature documentation increases procurement diligence.

02Why they buy

Unique selling points supported by stronger evidence

ArtiDock peer-reviewed publication: independent benchmarking and reference tooling are available for evaluation.
NVIDIA collaboration: third-party technical content describes integration and compute acceleration for large-scale screening workloads.

Unique selling points that are vendor-claimed and require validation

- Vendor-claimed high docking performance relative to selected baselines (performance claims require independent benchmarking on user targets). - Project success-rate and project-count claims (e.g., project counts or aggregated success rates) are vendor-reported and should be validated through contract-level references and data sharing. Areas where competitors likely have advantages - Public enterprise trust artifacts (security/compliance) - Larger installed base and ecosystem maturity (e.g., Schrödinger) - Proprietary experimental infrastructure or scaled biological datasets (e.g., Recursion/Exscientia in certain contexts)

03Field reports

Important limitation: lack of conventional software review coverage

RECEPTOR.AI is not broadly present on mainstream B2B review platforms (based on accessible sources):

Gartner Peer Insights: no accessible listing/reviews found.
G2 / TrustRadius / Capterra: no credible product review pages found.

This limited presence is common for niche TechBio discovery platforms but reduces the amount of publicly available user feedback.

Community/Social signal (Reddit, etc.)

Available Reddit mentions are sparse and mostly list-style or link drops rather than hands-on user feedback.

Example: a futurology thread lists RECEPTOR.AI among other companies without providing experiential pros/cons.

Partner/press quotes (proxy for “testimonials”)

Because user reviews are limited, partner press releases and announcements are the closest substitutes for public testimonials. These are vendor- and partner-issued statements and are not independent user reviews. Examples: - Sareum collaboration: describes use of Oracle.AI virtual screening and ADMET modeling; ArtiDock is described in partner materials as “ranked” in vendor communications. - BriaCell/BriaPro collaboration: describes RECEPTOR.AI supporting target assessment, hit identification, and lead optimization with emphasis on isoform selectivity. - Moexa partnership: vendor materials reference project counts and claimed acceleration through preclinical protocols. These announcements indicate market activity but are not independent validation of product performance.

Balanced interpretation of limited reviews

Positive interpretation: enterprise pharma users often do not leave public reviews due to NDAs and competitive secrecy.
Negative interpretation: lack of third-party reviews makes validation of support quality, reliability, usability, and implementation complexity more difficult. Buyers should seek references under NDA and run technical pilots.

04Best fit

Company sizes (typical)

Based on reported pricing bands and partnership style:

Biotech: ~20–300 employees; preclinical to clinical-stage biotechs seeking discovery acceleration without building large internal computational chemistry/ML teams.
Pharma: mid-sized to large pharma discovery units evaluating AI docking/virtual screening and selectivity workflows.

These are inferred; RECEPTOR.AI does not publish a formal ICP.

Industries/verticals

Biopharma drug discovery
Adjacent opportunities: peptide-based consumer applications (e.g., peptide skin care collaborations referenced in social posts)

Sources: receptor.ai partnerships; public social posts.

Roles and personas

VP/Head of Discovery, CSO
Computational chemistry leads
Medicinal chemistry leads
Structural biology/modeling leads
Alliance management and business development for partnered discovery

Pain points addressed

Low hit rates in ultra-large chemical spaces
Uncertain binding modes, including the presence of ions/cofactors/water
Selectivity challenges among similar isoforms
Targets with limited structural data (PPIs, cryptic pockets)

05The pitch

What the product does (core value proposition)

RECEPTOR.AI is a TechBio drug-discovery technology provider offering a multiplatform AI platform spanning: - Small molecules (virtual screening, lead optimization, selectivity optimization) - Peptides (de novo binder design and optimization toward permeability/oral availability) - Proximity/biologics & induced proximity modalities (e.g., degraders/molecular glues; PPI/ternary complex modeling) The company describes its value as supporting discovery teams in addressing structural uncertainty (cryptic/transient pockets, ambiguous binding modes), multiparameter trade-offs (potency vs. ADMET vs. selectivity), and high-throughput design choices from hit discovery through lead optimization. Vendor materials emphasize a hybrid approach combining machine learning (ML) and agent-based AI orchestration with physics-based modeling. Evidence from vendor materials: - Platform pages describe workflows such as pocket identification, SAR, multiparametric optimization, and agent-based AI orchestration. - Modules/brands referenced publicly include ArtiDock (docking), ADMETiQ/AdmetIQ (ADMET prediction), QuorumMap (chemical space navigation), and Oracle.AI (virtual screening platform). Note: naming appears inconsistent across pages (e.g., “ADMETiQ” vs “AdmetIQ”), which may create procurement ambiguity. Sources: receptor.ai home page and platform descriptions; QuorumMap article; Oracle.AI references in partnership announcements.

Target market and market positioning

RECEPTOR.AI primarily targets: - Pharma and biotech R&D organizations needing preclinical discovery support - Some academic groups (academic availability noted for ArtiDock API) - Teams working on challenging targets (PPIs, membrane proteins, cryptic pockets, isoform selectivity) The company positions itself as a hybrid partner-plus-platform model rather than a purely self-serve software tool: - Multiple press and partner announcements describe RECEPTOR.AI performing discovery work with partners (e.g., hit identification/lead optimization) in addition to selling licenses. Sources: receptor.ai About Us; partnership announcements (Moexa, Sareum, BriaCell/BriaPro, PRISM BioLab); NVIDIA technical blog.

Get a comprehensive analysis of RECEPTOR.AI including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Jun 25, 2026

01Common complaints

Formal security certification requirement
- If procurement requires publicly documented SOC 2 Type II or ISO 27001 certification prior to vendor consideration, RECEPTOR.AI’s public materials do not show these certifications and the vendor may not pass initial screening based solely on public information.
Need for an off-the-shelf, self-serve computational chemistry tool with a large public user community
- Organizations seeking a widely adopted, self-serve solution with extensive public training resources may prefer established toolkits or vendors with larger public communities.
Lack of experimental feedback capability
- Programs without assay throughput or synthesis capacity to support iterative design-test cycles may see limited ROI from any AI discovery platform.
Requirement for extensive public reviews
- If vendor selection heavily depends on Gartner/G2/TrustRadius-style public reviews, RECEPTOR.AI’s public presence appears limited and will require reference checks under NDA and pilots.
Expectation of guaranteed clinical translation outcomes
- RECEPTOR.AI focuses on preclinical discovery work; improvements in computational metrics do not guarantee clinical success.

Deal disqualifiers

Formal requirement for publicly documented SOC2/ISO27001 evidence prior to vendor consideration
Need for an off-the-shelf, self-serve SaaS trial with public pricing
Requirement for numerous public customer reviews or references without NDAs

Limitations acknowledged by vendor or present in peer-reviewed artifacts

Vendor materials generally emphasize ongoing improvement but do not list extensive limitations publicly. The ArtiDock paper notes broader issues in ML docking, such as chemical validity of predicted poses, and identifies future work areas (improving geometrical/chemical validity and native scoring).

Roadmap and continuity

Some vendor posts indicate future integrations (e.g., with third-party cloud APIs) and continued model updates; timelines are not always definitive.

Scale considerations

No explicit scale-breaking points are disclosed. Third-party technical content suggests large-scale screening is feasible with sufficient GPU resources, but buyers should clarify cost and throughput assumptions.

Security and compliance gaps

No publicly documented SOC2/ISO certifications were located.
Limited public enterprise feature documentation increases procurement diligence.

02Why they buy

Unique selling points supported by stronger evidence

ArtiDock peer-reviewed publication: independent benchmarking and reference tooling are available for evaluation.
NVIDIA collaboration: third-party technical content describes integration and compute acceleration for large-scale screening workloads.

Unique selling points that are vendor-claimed and require validation

Vendor-claimed high docking performance relative to selected baselines (performance claims require independent benchmarking on user targets).
Project success-rate and project-count claims (e.g., project counts or aggregated success rates) are vendor-reported and should be validated through contract-level references and data sharing.

Areas where competitors likely have advantages

Public enterprise trust artifacts (security/compliance)
Larger installed base and ecosystem maturity (e.g., Schrödinger)
Proprietary experimental infrastructure or scaled biological datasets (e.g., Recursion/Exscientia in certain contexts)

03Field reports

Important limitation: lack of conventional software review coverage

RECEPTOR.AI is not broadly present on mainstream B2B review platforms (based on accessible sources):

Gartner Peer Insights: no accessible listing/reviews found.
G2 / TrustRadius / Capterra: no credible product review pages found.

This limited presence is common for niche TechBio discovery platforms but reduces the amount of publicly available user feedback.

Community/Social signal (Reddit, etc.)

Available Reddit mentions are sparse and mostly list-style or link drops rather than hands-on user feedback.

Example: a futurology thread lists RECEPTOR.AI among other companies without providing experiential pros/cons.

Partner/press quotes (proxy for “testimonials”)

Examples:

Sareum collaboration: describes use of Oracle.AI virtual screening and ADMET modeling; ArtiDock is described in partner materials as “ranked” in vendor communications.
BriaCell/BriaPro collaboration: describes RECEPTOR.AI supporting target assessment, hit identification, and lead optimization with emphasis on isoform selectivity.
Moexa partnership: vendor materials reference project counts and claimed acceleration through preclinical protocols.

These announcements indicate market activity but are not independent validation of product performance.

Balanced interpretation of limited reviews

Positive interpretation: enterprise pharma users often do not leave public reviews due to NDAs and competitive secrecy.
Negative interpretation: lack of third-party reviews makes validation of support quality, reliability, usability, and implementation complexity more difficult. Buyers should seek references under NDA and run technical pilots.

04Best fit

Company sizes (typical)

Based on reported pricing bands and partnership style:

Biotech: ~20–300 employees; preclinical to clinical-stage biotechs seeking discovery acceleration without building large internal computational chemistry/ML teams.
Pharma: mid-sized to large pharma discovery units evaluating AI docking/virtual screening and selectivity workflows.

These are inferred; RECEPTOR.AI does not publish a formal ICP.

Industries/verticals

Biopharma drug discovery
Adjacent opportunities: peptide-based consumer applications (e.g., peptide skin care collaborations referenced in social posts)

Sources: receptor.ai partnerships; public social posts.

Roles and personas

VP/Head of Discovery, CSO
Computational chemistry leads
Medicinal chemistry leads
Structural biology/modeling leads
Alliance management and business development for partnered discovery

Pain points addressed

Low hit rates in ultra-large chemical spaces
Uncertain binding modes, including the presence of ions/cofactors/water
Selectivity challenges among similar isoforms
Targets with limited structural data (PPIs, cryptic pockets)

05The pitch

What the product does (core value proposition)

RECEPTOR.AI is a TechBio drug-discovery technology provider offering a multiplatform AI platform spanning:

Small molecules (virtual screening, lead optimization, selectivity optimization)
Peptides (de novo binder design and optimization toward permeability/oral availability)
Proximity/biologics & induced proximity modalities (e.g., degraders/molecular glues; PPI/ternary complex modeling)

The company describes its value as supporting discovery teams in addressing structural uncertainty (cryptic/transient pockets, ambiguous binding modes), multiparameter trade-offs (potency vs. ADMET vs. selectivity), and high-throughput design choices from hit discovery through lead optimization. Vendor materials emphasize a hybrid approach combining machine learning (ML) and agent-based AI orchestration with physics-based modeling.

Evidence from vendor materials:

Platform pages describe workflows such as pocket identification, SAR, multiparametric optimization, and agent-based AI orchestration.
Modules/brands referenced publicly include ArtiDock (docking), ADMETiQ/AdmetIQ (ADMET prediction), QuorumMap (chemical space navigation), and Oracle.AI (virtual screening platform). Note: naming appears inconsistent across pages (e.g., “ADMETiQ” vs “AdmetIQ”), which may create procurement ambiguity.

Sources: receptor.ai home page and platform descriptions; QuorumMap article; Oracle.AI references in partnership announcements.

Target market and market positioning

RECEPTOR.AI primarily targets:

Pharma and biotech R&D organizations needing preclinical discovery support
Some academic groups (academic availability noted for ArtiDock API)
Teams working on challenging targets (PPIs, membrane proteins, cryptic pockets, isoform selectivity)

The company positions itself as a hybrid partner-plus-platform model rather than a purely self-serve software tool:

Multiple press and partner announcements describe RECEPTOR.AI performing discovery work with partners (e.g., hit identification/lead optimization) in addition to selling licenses.

Sources: receptor.ai About Us; partnership announcements (Moexa, Sareum, BriaCell/BriaPro, PRISM BioLab); NVIDIA technical blog.

Get a comprehensive analysis of RECEPTOR.AI including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →